CRISPR Therapeutics' CASGEVY receives EU conditional approval for sickle cell disease and beta thalassemia

CRISPR Therapeutics AG

European Commission granted conditional marketing authorization for CASGEVY (exa-cel).
Indicated for patients 12+ with severe sickle cell disease or transfusion-dependent beta thalassemia.
Eligible when HSCT is appropriate and no HLA-matched related donor is available.
CMA valid for one year, renewable annually with ongoing data review.
CASGEVY is a CRISPR/Cas9 gene-edited therapy jointly developed with Vertex.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.